|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC35C2 |
Gene summary for SLC35C2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC35C2 | Gene ID | 51006 |
| Gene name | solute carrier family 35 member C2 | |
| Gene Alias | BA394O2.1 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9NQQ7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51006 | SLC35C2 | LZE4T | Human | Esophagus | ESCC | 6.82e-15 | 2.97e-01 | 0.0811 |
| 51006 | SLC35C2 | LZE7T | Human | Esophagus | ESCC | 3.44e-07 | 3.23e-01 | 0.0667 |
| 51006 | SLC35C2 | LZE8T | Human | Esophagus | ESCC | 2.97e-09 | 2.25e-01 | 0.067 |
| 51006 | SLC35C2 | LZE20T | Human | Esophagus | ESCC | 1.55e-06 | 2.79e-01 | 0.0662 |
| 51006 | SLC35C2 | LZE22D1 | Human | Esophagus | HGIN | 8.57e-03 | 1.82e-01 | 0.0595 |
| 51006 | SLC35C2 | LZE22T | Human | Esophagus | ESCC | 1.07e-02 | 3.23e-01 | 0.068 |
| 51006 | SLC35C2 | LZE24T | Human | Esophagus | ESCC | 6.41e-23 | 4.64e-01 | 0.0596 |
| 51006 | SLC35C2 | LZE21T | Human | Esophagus | ESCC | 4.42e-05 | 2.74e-01 | 0.0655 |
| 51006 | SLC35C2 | LZE6T | Human | Esophagus | ESCC | 1.06e-07 | 1.90e-01 | 0.0845 |
| 51006 | SLC35C2 | P1T-E | Human | Esophagus | ESCC | 5.71e-14 | 7.10e-01 | 0.0875 |
| 51006 | SLC35C2 | P2T-E | Human | Esophagus | ESCC | 3.04e-39 | 5.66e-01 | 0.1177 |
| 51006 | SLC35C2 | P4T-E | Human | Esophagus | ESCC | 2.05e-15 | 3.79e-01 | 0.1323 |
| 51006 | SLC35C2 | P5T-E | Human | Esophagus | ESCC | 4.57e-12 | 2.02e-01 | 0.1327 |
| 51006 | SLC35C2 | P8T-E | Human | Esophagus | ESCC | 1.33e-29 | 5.51e-01 | 0.0889 |
| 51006 | SLC35C2 | P9T-E | Human | Esophagus | ESCC | 2.48e-12 | 3.10e-01 | 0.1131 |
| 51006 | SLC35C2 | P10T-E | Human | Esophagus | ESCC | 7.98e-43 | 7.76e-01 | 0.116 |
| 51006 | SLC35C2 | P11T-E | Human | Esophagus | ESCC | 2.98e-20 | 7.35e-01 | 0.1426 |
| 51006 | SLC35C2 | P12T-E | Human | Esophagus | ESCC | 9.07e-27 | 5.04e-01 | 0.1122 |
| 51006 | SLC35C2 | P15T-E | Human | Esophagus | ESCC | 2.19e-25 | 5.21e-01 | 0.1149 |
| 51006 | SLC35C2 | P16T-E | Human | Esophagus | ESCC | 1.98e-38 | 7.18e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001593116 | Esophagus | HGIN | nucleobase-containing compound transport | 57/2587 | 222/18723 | 1.76e-06 | 6.52e-05 | 57 |
| GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00072197 | Esophagus | ESCC | Notch signaling pathway | 106/8552 | 172/18723 | 1.74e-05 | 1.55e-04 | 106 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00085935 | Esophagus | ESCC | regulation of Notch signaling pathway | 59/8552 | 95/18723 | 9.12e-04 | 4.65e-03 | 59 |
| GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
| GO:00159316 | Liver | Cirrhotic | nucleobase-containing compound transport | 87/4634 | 222/18723 | 1.25e-06 | 2.52e-05 | 87 |
| GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:1901264 | Liver | HCC | carbohydrate derivative transport | 48/7958 | 80/18723 | 1.19e-03 | 6.62e-03 | 48 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
| GO:00072196 | Oral cavity | OSCC | Notch signaling pathway | 92/7305 | 172/18723 | 7.84e-05 | 6.08e-04 | 92 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC35C2 | SNV | Missense_Mutation | novel | c.469T>C | p.Ser157Pro | p.S157P | Q9NQQ7 | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| SLC35C2 | insertion | In_Frame_Ins | novel | c.687_688insTGC | p.Thr229_Met230insCys | p.T229_M230insC | Q9NQQ7 | protein_coding | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC35C2 | SNV | Missense_Mutation | rs778808342 | c.913N>A | p.Gly305Ser | p.G305S | Q9NQQ7 | protein_coding | deleterious(0.04) | probably_damaging(0.974) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC35C2 | SNV | Missense_Mutation | c.767N>G | p.Ser256Cys | p.S256C | Q9NQQ7 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| SLC35C2 | SNV | Missense_Mutation | novel | c.570N>G | p.Phe190Leu | p.F190L | Q9NQQ7 | protein_coding | deleterious(0.01) | possibly_damaging(0.886) | TCGA-VS-A8EB-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | PD |
| SLC35C2 | SNV | Missense_Mutation | novel | c.1147G>A | p.Glu383Lys | p.E383K | Q9NQQ7 | protein_coding | tolerated(0.07) | benign(0.022) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| SLC35C2 | SNV | Missense_Mutation | c.419N>T | p.Ser140Leu | p.S140L | Q9NQQ7 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| SLC35C2 | SNV | Missense_Mutation | rs187394710 | c.496N>T | p.Arg166Cys | p.R166C | Q9NQQ7 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SLC35C2 | SNV | Missense_Mutation | c.896N>A | p.Leu299His | p.L299H | Q9NQQ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3819-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC35C2 | SNV | Missense_Mutation | rs202041610 | c.1117N>T | p.Arg373Trp | p.R373W | Q9NQQ7 | protein_coding | deleterious(0.01) | possibly_damaging(0.534) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |